Santhera publiziert Zeitplan für die Aktienzusammenlegung
June 29, 2023 01:00 ET
|
Santhera Pharmaceuticals Holding AG
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO. Ad-hoc-Mitteilung gemäss Art. 53 KR Pratteln, Schweiz, 29. Juni...
Santhera Publishes Timeline of the Reverse Share Split
June 29, 2023 01:00 ET
|
Santhera Pharmaceuticals Holding AG
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO. Ad hoc announcement pursuant to Art. 53 LR Pratteln,...
Santhera’s Aktionäre stimmen an heutiger Generalversammlung allen Anträgen des Verwaltungsrats zu
June 27, 2023 08:30 ET
|
Santhera Pharmaceuticals Holding AG
Pratteln, Schweiz, 27. Juni 2023 – Santhera Pharmaceuticals (SIX: SANN) gibt bekannt, dass die Aktionäre an der heutigen Generalversammlung (GV) in Pratteln, Schweiz, allen Anträgen des...
Shareholders Approve all Board Proposals at Today’s Annual General Meeting
June 27, 2023 08:30 ET
|
Santhera Pharmaceuticals Holding AG
Pratteln, Switzerland, June 27, 2023 – Santhera Pharmaceuticals (SIX: SANN) announces that its shareholders approved all motions by the Board of Directors at the Annual General Meeting (AGM) held...
Santhera vergibt exklusive Nordamerika-Lizenz für Vamorolone an Catalyst Pharmaceuticals in einer Transaktion im Wert von bis zu USD 231 Millionen zuzüglich Lizenzgebühren
June 20, 2023 01:00 ET
|
Santhera Pharmaceuticals Holding AG
Ad-hoc-Mitteilung gemäss Art. 53 KR Santhera wird heute um 14:30 MESZ / 13:30 BST / 08:30 EDT eine Telefonkonferenz durchführen. Details dazu am Ende dieser Mitteilung. Santhera erhält USD 90...
Santhera Grants Exclusive North America License for Vamorolone to Catalyst Pharmaceuticals in Deal Valued at up to USD 231 Million Plus Royalties
June 20, 2023 01:00 ET
|
Santhera Pharmaceuticals Holding AG
Ad hoc announcement pursuant to Art. 53 LR A conference call will be held today at 14:30 CEST / 13:30 BST / 08:30 EDT. Details are at the end of this news release. Santhera will receive USD...
Santhera veröffentlicht Einladung zur ordentlichen Generalversammlung
June 06, 2023 01:00 ET
|
Santhera Pharmaceuticals Holding AG
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO. Ad-hoc-Mitteilung gemäss Art. 53 KR Pratteln, Schweiz, 6. Juni...
Santhera Publishes Agenda for its Annual General Meeting
June 06, 2023 01:00 ET
|
Santhera Pharmaceuticals Holding AG
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO. Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland,...
Santhera veröffentlicht Jahresbericht 2022
May 31, 2023 17:50 ET
|
Santhera Pharmaceuticals Holding AG
Ad-hoc-Mitteilung gemäss Art. 53 KR Pratteln, Schweiz, 31. Mai 2023 – Santhera Pharmaceuticals (SIX: SANN) gibt die Veröffentlichung des Jahresberichts 2022 mit den vollständig geprüften Ergebnissen...
Santhera Publishes Annual Report 2022
May 31, 2023 17:50 ET
|
Santhera Pharmaceuticals Holding AG
Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, May 31, 2023 – Santhera Pharmaceuticals (SIX: SANN) announces the publication of its Annual Report 2022 with fully audited results...